Xencor Inc (XNCR) 19.35 $XNCR
Should You Buy Xencor (XNCR) Ahead of Earnings?
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 9:03AM CDT
Xencor (XNCR) looks poised to beat analyst estimates this earnings season, with a favorable Zacks Rank and an ESP in positive territory.
XNCR: 19.35 (+0.41)
Xencor to Host Second Quarter 2016 Financial Results Webcast and Conference Call on August 2, 2016
PR Newswire - Tue Jul 26, 7:00AM CDT
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, announced that it will release second quarter 2016 financial results after the market closes on Tuesday, August 2, 2016. Xencor management will host a webcast and conference call the same day at 4:30 p.m. ET (1:30 p.m. PT) to discuss the financial results and provide a corporate update.
XNCR: 19.35 (+0.41)
Why Xencor (XNCR) is Poised to Beat Earnings Estimates Again
Zacks Equity Research - Zacks Investment Research - Wed Jul 13, 7:54AM CDT
Xencor (XNCR) boasts a favorable Zacks Rank and a positive Earnings ESP, which is a great sign of a coming earnings beat.
XNCR: 19.35 (+0.41)
The Zacks Analyst Blog Highlights: AK Steel, Gulfport Energy, Hecla Mining, Carrizo Oil & Gas and Xencor
Zacks Equity Research - Zacks Investment Research - Tue Jul 12, 8:30AM CDT
The Zacks Analyst Blog Highlights: AK Steel, Gulfport Energy, Hecla Mining, Carrizo Oil & Gas and Xencor
HL: 6.60 (+0.11), AKS: 6.25 (-0.31), CRZO: 29.89 (-2.91), XNCR: 19.35 (+0.41), GPOR: 27.86 (-1.23)
5 Growth Stocks Poised for Huge Earnings Beats
Zacks Equity Research - Zacks Investment Research - Mon Jul 11, 2:31PM CDT
These 5 stocks look poised to post huge earnings beats in the coming season, and have great growth metrics as well.
HL: 6.60 (+0.11), AKS: 6.25 (-0.31), CRZO: 29.89 (-2.91), XNCR: 19.35 (+0.41), GPOR: 27.86 (-1.23)
Can The Uptrend Continue for Xencor (XNCR)?
Zacks Equity Research - Zacks Investment Research - Wed Jul 06, 3:17AM CDT
Investors certainly have to be happy with Xencor Inc (XNCR) and its short term performance
XNCR: 19.35 (+0.41)
Xencor Reports Complete Data Results from XmAb7195 Phase 1a Trial Showing Rapid Reduction of Serum IgE in High IgE Atopic Subjects at ATS 2016 International Conference
PR Newswire - Wed May 18, 11:00AM CDT
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that it presented complete data results from a Phase 1a, first-in-human study for XmAb®7195. XmAb7195 was generally well tolerated with transient, asymptomatic thrombocytopenia reported at doses greater-than or equal to 2.0 mg/kg, and induced rapid and extensive depletion of serum IgE at all doses tested, including in high IgE subjects. Results of this study support further development in a multiple ascending dose study with subcutaneous administration, expected to begin in 2016. Data are being presented Wednesday May 18, 2016 at 9:00 a.m. PT at the American Thoracic Society (ATS) 2016 International Conference in San Francisco, CA (A6476: Poster Board Number 407).
XNCR: 19.35 (+0.41)
Xencor to Present at Upcoming Investor Conferences
PR Newswire - Tue May 17, 7:00AM CDT
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that Bassil Dahiyat, president and chief executive officer, will present a corporate overview at two upcoming conferences:
XNCR: 19.35 (+0.41)
Xencor reports 1Q loss
Automated Insights - Mon May 02, 3:57PM CDT
MONROVIA, Calif. (AP) _ Xencor Inc. (XNCR) on Monday reported a loss of $6.4 million in its first quarter.
XNCR: 19.35 (+0.41)
Xencor to Host First Quarter 2016 Financial Results Webcast and Conference Call on May 2, 2016
PR Newswire - Mon Apr 25, 7:00AM CDT
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, announced that it will release first quarter 2016 financial results after the market closes on Monday, May 2, 2016. Xencor management will host a webcast and conference call the same day at 4:30 p.m. ET (1:30 p.m. PT) to discuss the financial results and provide a corporate update.
XNCR: 19.35 (+0.41)
Xencor (XNCR) Catches Eye: Stock Adds 6.9% in Session
Zacks Equity Research - Zacks Investment Research - Wed Mar 09, 7:15AM CST
Xencor, Inc. (XNCR) shares rose almost 7% in the last trading session.
EARS: 4.14 (+0.13), XNCR: 19.35 (+0.41)
Xencor Reports Fourth Quarter and Full Year 2015 Financial Results
PR Newswire - Mon Mar 07, 3:02PM CST
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today reported financial results for the fourth quarter and full year ended December 31, 2015 and provided a review of 2015 and recent business and clinical highlights.
AMGN: 174.16 (+2.13), XNCR: 19.35 (+0.41)
Xencor Initiates Two Phase 2 Trials of XmAb5871 in IgG4-Related Disease and Systemic Lupus Erythematosus
PR Newswire - Mon Mar 07, 3:01PM CST
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced dosing the first patient in a Phase 2 trial of XmAb®5871 in patients with IgG4-Related Disease (IgG4-RD). The Company also announced dosing the first patient in a Phase 2 trial of XmAb5871 in patients with Systemic Lupus Erythematosus (SLE).
XNCR: 19.35 (+0.41)
Zika Virus and Potential Effect on Olympics
ACCESSWIRE - Wed Feb 10, 8:01AM CST
BiotechMarketReport.com identifies PositiveID Corporation (PSID) as a Solution
TRVN: 6.39 (+0.12), XNCR: 19.35 (+0.41), PDLI: 3.55 (+0.03)
Xencor to Present at Two Upcoming Conferences in February
PR Newswire - Wed Feb 03, 7:00AM CST
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that company management will present a corporate overview at two upcoming conferences in February:
XNCR: 19.35 (+0.41)
Global Next-Generation Antibody Therapeutics Market - Size, Share, Development, Growth & Demand Forecast to 2020
M2 - Wed Jan 27, 10:17AM CST
Research and Markets (http://www.researchandmarkets.com/research/2pc7jv/global) has announced the addition of the "Global Next-Generation Antibody Therapeutics Market Size, Share, Development, Growth and Demand Forecast to 2020" report to their offering. The global next-generation antibody therapeutics market was worth $ 1,328.3 million in 2014, and it is expected to grow at a CAGR of 44% during 2015-2020. Next-generation antibody therapeutics market is escalating with high growth rate due to growing prevalence of chronic diseases. Some of the major reasons leading to increase in number of chronic disease cases include unhealthy lifestyle, poor diet, and addictions, such as smoking, and others. The next-generation antibody therapeutics industry has made huge growth in the recent years. The growing healthcare expenditure has increased the overall research and development investment by various organizations. This leads to the growth of global next-generation antibody therapeutics market. The Autoimmune/Inflammatory market is growing at an average annual growth rate of over 46.4%. The Fc Engineered Antibodies market on the other hand grew at a CAGR of 56.8% during 2015-2020. The restraints associated with next-generation antibody therapeutics market include high cost, stringent regulatory requirements and time consuming approval process of drugs. A significant capital investment is required for the research and manufacturing of next-generation therapeutics. Key Topics Covered: Chapter 1. Research Scope & Methodology Chapter 2. Executive Summary Chapter 3. Market Outlook Chapter 4. Next-Generation Antibody Therapeutics Drug Pipeline Analysis Chapter 5. Global Market Size And Forecast (2014 - 2020) Chapter 6. Next-Generation Antibody Therapeutics Market Breakdown By Therapeutic Area Chapter 7. Next-Generation Antibody Therapeutics Market Breakdown By Technology Chapter 8. Next-Generation Antibody Therapeutics Market Breakdown By Geography Chapter 9. Competitive Positioning And Market Share Analysis Chapter 10. Company Profiles Companies Mentioned: - Amgen Inc. - AstraZeneca PLC. - Bayer AG - Biogen - Bristol-Myers Squibb Company - Dyax Corp. - F. Hoffmann-La Roche Ltd - ImmunoGen Inc. - Kyowa Hakko Kirin Co. Ltd. - Pfizer Inc. - Seattle Genetics Inc. - Takeda Pharmaceuticals Company Limited - Xencor Inc. For more information visit http://www.researchandmarkets.com/research/2pc7jv/global
SGEN: 49.22 (+1.16), PFE: 37.31 (+0.42), AZN: 33.84 (-0.30), IMGN: 2.96 (+0.18), AMGN: 174.16 (+2.13), BMY: 76.19 (+1.38), XNCR: 19.35 (+0.41), DYAX: 38.04 (-0.37)
Emergent Technologies Portfolio Company Enters into License Agreement with Xencor
BusinessWire - Tue Jan 12, 5:00AM CST
Emergent Technologies, Inc. announced today that its portfolio company, Receptor Logic, has entered into an exclusive License Agreement with Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for autoimmune diseases, asthma and allergic diseases, and cancer. The agreement gives Xencor the exclusive worldwide rights to use a T-Cell Receptor Mimic (TCRm) monoclonal antibody against the target NY-ESO1, developed by Receptor Logic, for cancer treatment.
XNCR: 19.35 (+0.41)
Xencor Announces Change to Board of Directors
PR Newswire - Mon Jan 11, 7:00AM CST
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, announced that John Stafford, III has notified the company of his decision to resign effective January 5, 2016 from the Board of Directors after 18 years of service to the company.
XNCR: 19.35 (+0.41)
National Institutes of Health Initiates Phase 1 Trial of VRC01LS Anti-HIV Therapeutic Antibody Using Xencor's Xtend Fc Technology
PR Newswire - Thu Jan 07, 7:00AM CST
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, announced that the National Institutes of Health (NIH) has initiated a Phase 1 clinical trial of VRC01LS, a therapeutic antibody for the treatment of HIV that uses Xencor's Xtend antibody half-life extension technology.
XNCR: 19.35 (+0.41)
Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance
BusinessWire - Wed Dec 16, 6:00AM CST
Loncar Investments, LLC today announced the result of the semi-annual rebalance and reconstitution of the Loncar Cancer Immunotherapy Index, a group of the top 30 companies developing cancer immunotherapy treatments and finding new ways to use the body's immune system to fight cancer.
NWBO: 0.42 (-0.02), TSRO: 95.15 (+1.91), CTMX: 10.25 (+0.19), NK: 7.27 (+0.44), CNCR: 24.77 (+0.29), SRNE: 6.52 (+0.23), XNCR: 19.35 (+0.41), ONTY: 1.21 (+0.02), CYAD: 24.81 (-0.17)
Should You Buy Xencor (XNCR) Ahead of Earnings?
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 9:03AM CDT
Xencor (XNCR) looks poised to beat analyst estimates this earnings season, with a favorable Zacks Rank and an ESP in positive territory.
XNCR: 19.35 (+0.41)
Xencor to Host Second Quarter 2016 Financial Results Webcast and Conference Call on August 2, 2016
PR Newswire - Tue Jul 26, 7:00AM CDT
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, announced that it will release second quarter 2016 financial results after the market closes on Tuesday, August 2, 2016. Xencor management will host a webcast and conference call the same day at 4:30 p.m. ET (1:30 p.m. PT) to discuss the financial results and provide a corporate update.
XNCR: 19.35 (+0.41)
Why Xencor (XNCR) is Poised to Beat Earnings Estimates Again
Zacks Equity Research - Zacks Investment Research - Wed Jul 13, 7:54AM CDT
Xencor (XNCR) boasts a favorable Zacks Rank and a positive Earnings ESP, which is a great sign of a coming earnings beat.
XNCR: 19.35 (+0.41)
The Zacks Analyst Blog Highlights: AK Steel, Gulfport Energy, Hecla Mining, Carrizo Oil & Gas and Xencor
Zacks Equity Research - Zacks Investment Research - Tue Jul 12, 8:30AM CDT
The Zacks Analyst Blog Highlights: AK Steel, Gulfport Energy, Hecla Mining, Carrizo Oil & Gas and Xencor
HL: 6.60 (+0.11), AKS: 6.25 (-0.31), CRZO: 29.89 (-2.91), XNCR: 19.35 (+0.41), GPOR: 27.86 (-1.23)
5 Growth Stocks Poised for Huge Earnings Beats
Zacks Equity Research - Zacks Investment Research - Mon Jul 11, 2:31PM CDT
These 5 stocks look poised to post huge earnings beats in the coming season, and have great growth metrics as well.
HL: 6.60 (+0.11), AKS: 6.25 (-0.31), CRZO: 29.89 (-2.91), XNCR: 19.35 (+0.41), GPOR: 27.86 (-1.23)
Can The Uptrend Continue for Xencor (XNCR)?
Zacks Equity Research - Zacks Investment Research - Wed Jul 06, 3:17AM CDT
Investors certainly have to be happy with Xencor Inc (XNCR) and its short term performance
XNCR: 19.35 (+0.41)
Xencor Reports Complete Data Results from XmAb7195 Phase 1a Trial Showing Rapid Reduction of Serum IgE in High IgE Atopic Subjects at ATS 2016 International Conference
PR Newswire - Wed May 18, 11:00AM CDT
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that it presented complete data results from a Phase 1a, first-in-human study for XmAb®7195. XmAb7195 was generally well tolerated with transient, asymptomatic thrombocytopenia reported at doses greater-than or equal to 2.0 mg/kg, and induced rapid and extensive depletion of serum IgE at all doses tested, including in high IgE subjects. Results of this study support further development in a multiple ascending dose study with subcutaneous administration, expected to begin in 2016. Data are being presented Wednesday May 18, 2016 at 9:00 a.m. PT at the American Thoracic Society (ATS) 2016 International Conference in San Francisco, CA (A6476: Poster Board Number 407).
XNCR: 19.35 (+0.41)
Xencor to Present at Upcoming Investor Conferences
PR Newswire - Tue May 17, 7:00AM CDT
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that Bassil Dahiyat, president and chief executive officer, will present a corporate overview at two upcoming conferences:
XNCR: 19.35 (+0.41)
Xencor reports 1Q loss
Automated Insights - Mon May 02, 3:57PM CDT
MONROVIA, Calif. (AP) _ Xencor Inc. (XNCR) on Monday reported a loss of $6.4 million in its first quarter.
XNCR: 19.35 (+0.41)
Xencor to Host First Quarter 2016 Financial Results Webcast and Conference Call on May 2, 2016
PR Newswire - Mon Apr 25, 7:00AM CDT
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, announced that it will release first quarter 2016 financial results after the market closes on Monday, May 2, 2016. Xencor management will host a webcast and conference call the same day at 4:30 p.m. ET (1:30 p.m. PT) to discuss the financial results and provide a corporate update.
XNCR: 19.35 (+0.41)
Xencor (XNCR) Catches Eye: Stock Adds 6.9% in Session
Zacks Equity Research - Zacks Investment Research - Wed Mar 09, 7:15AM CST
Xencor, Inc. (XNCR) shares rose almost 7% in the last trading session.
EARS: 4.14 (+0.13), XNCR: 19.35 (+0.41)
Xencor Reports Fourth Quarter and Full Year 2015 Financial Results
PR Newswire - Mon Mar 07, 3:02PM CST
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today reported financial results for the fourth quarter and full year ended December 31, 2015 and provided a review of 2015 and recent business and clinical highlights.
AMGN: 174.16 (+2.13), XNCR: 19.35 (+0.41)
Xencor Initiates Two Phase 2 Trials of XmAb5871 in IgG4-Related Disease and Systemic Lupus Erythematosus
PR Newswire - Mon Mar 07, 3:01PM CST
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced dosing the first patient in a Phase 2 trial of XmAb®5871 in patients with IgG4-Related Disease (IgG4-RD). The Company also announced dosing the first patient in a Phase 2 trial of XmAb5871 in patients with Systemic Lupus Erythematosus (SLE).
XNCR: 19.35 (+0.41)
Zika Virus and Potential Effect on Olympics
ACCESSWIRE - Wed Feb 10, 8:01AM CST
BiotechMarketReport.com identifies PositiveID Corporation (PSID) as a Solution
TRVN: 6.39 (+0.12), XNCR: 19.35 (+0.41), PDLI: 3.55 (+0.03)
Xencor to Present at Two Upcoming Conferences in February
PR Newswire - Wed Feb 03, 7:00AM CST
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that company management will present a corporate overview at two upcoming conferences in February:
XNCR: 19.35 (+0.41)
Global Next-Generation Antibody Therapeutics Market - Size, Share, Development, Growth & Demand Forecast to 2020
M2 - Wed Jan 27, 10:17AM CST
Research and Markets (http://www.researchandmarkets.com/research/2pc7jv/global) has announced the addition of the "Global Next-Generation Antibody Therapeutics Market Size, Share, Development, Growth and Demand Forecast to 2020" report to their offering. The global next-generation antibody therapeutics market was worth $ 1,328.3 million in 2014, and it is expected to grow at a CAGR of 44% during 2015-2020. Next-generation antibody therapeutics market is escalating with high growth rate due to growing prevalence of chronic diseases. Some of the major reasons leading to increase in number of chronic disease cases include unhealthy lifestyle, poor diet, and addictions, such as smoking, and others. The next-generation antibody therapeutics industry has made huge growth in the recent years. The growing healthcare expenditure has increased the overall research and development investment by various organizations. This leads to the growth of global next-generation antibody therapeutics market. The Autoimmune/Inflammatory market is growing at an average annual growth rate of over 46.4%. The Fc Engineered Antibodies market on the other hand grew at a CAGR of 56.8% during 2015-2020. The restraints associated with next-generation antibody therapeutics market include high cost, stringent regulatory requirements and time consuming approval process of drugs. A significant capital investment is required for the research and manufacturing of next-generation therapeutics. Key Topics Covered: Chapter 1. Research Scope & Methodology Chapter 2. Executive Summary Chapter 3. Market Outlook Chapter 4. Next-Generation Antibody Therapeutics Drug Pipeline Analysis Chapter 5. Global Market Size And Forecast (2014 - 2020) Chapter 6. Next-Generation Antibody Therapeutics Market Breakdown By Therapeutic Area Chapter 7. Next-Generation Antibody Therapeutics Market Breakdown By Technology Chapter 8. Next-Generation Antibody Therapeutics Market Breakdown By Geography Chapter 9. Competitive Positioning And Market Share Analysis Chapter 10. Company Profiles Companies Mentioned: - Amgen Inc. - AstraZeneca PLC. - Bayer AG - Biogen - Bristol-Myers Squibb Company - Dyax Corp. - F. Hoffmann-La Roche Ltd - ImmunoGen Inc. - Kyowa Hakko Kirin Co. Ltd. - Pfizer Inc. - Seattle Genetics Inc. - Takeda Pharmaceuticals Company Limited - Xencor Inc. For more information visit http://www.researchandmarkets.com/research/2pc7jv/global
SGEN: 49.22 (+1.16), PFE: 37.31 (+0.42), AZN: 33.84 (-0.30), IMGN: 2.96 (+0.18), AMGN: 174.16 (+2.13), BMY: 76.19 (+1.38), XNCR: 19.35 (+0.41), DYAX: 38.04 (-0.37)
Emergent Technologies Portfolio Company Enters into License Agreement with Xencor
BusinessWire - Tue Jan 12, 5:00AM CST
Emergent Technologies, Inc. announced today that its portfolio company, Receptor Logic, has entered into an exclusive License Agreement with Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for autoimmune diseases, asthma and allergic diseases, and cancer. The agreement gives Xencor the exclusive worldwide rights to use a T-Cell Receptor Mimic (TCRm) monoclonal antibody against the target NY-ESO1, developed by Receptor Logic, for cancer treatment.
XNCR: 19.35 (+0.41)
Xencor Announces Change to Board of Directors
PR Newswire - Mon Jan 11, 7:00AM CST
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, announced that John Stafford, III has notified the company of his decision to resign effective January 5, 2016 from the Board of Directors after 18 years of service to the company.
XNCR: 19.35 (+0.41)
National Institutes of Health Initiates Phase 1 Trial of VRC01LS Anti-HIV Therapeutic Antibody Using Xencor's Xtend Fc Technology
PR Newswire - Thu Jan 07, 7:00AM CST
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, announced that the National Institutes of Health (NIH) has initiated a Phase 1 clinical trial of VRC01LS, a therapeutic antibody for the treatment of HIV that uses Xencor's Xtend antibody half-life extension technology.
XNCR: 19.35 (+0.41)
Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance
BusinessWire - Wed Dec 16, 6:00AM CST
Loncar Investments, LLC today announced the result of the semi-annual rebalance and reconstitution of the Loncar Cancer Immunotherapy Index, a group of the top 30 companies developing cancer immunotherapy treatments and finding new ways to use the body's immune system to fight cancer.
NWBO: 0.42 (-0.02), TSRO: 95.15 (+1.91), CTMX: 10.25 (+0.19), NK: 7.27 (+0.44), CNCR: 24.77 (+0.29), SRNE: 6.52 (+0.23), XNCR: 19.35 (+0.41), ONTY: 1.21 (+0.02), CYAD: 24.81 (-0.17)
